HDAC9 and hypoparathyroidism-retardation-dysmorphism syndrome: HDAC inhibitor Entinostat significantly promoted HRD-EXCUTE signature (Supplementary Fig. S4D), which could potentially enhance immunogenicity in HRD tumors.